Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 495,295 |
|
|||||
| News | - | ||||||
| Day High | 2.41 | Low High |
|||||
| Day Low | 2.31 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Erasca Inc | ERAS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.02 | 0.85% | 2.375 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.32 | 2.31 | 2.41 | 2.375 | 2.355 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,103 | 495,295 | US$ 2.36 | US$ 1,170,379 | - | 1.51 - 3.16 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:29:39 | 2 | US$ 2.43 | USD |
Erasca Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 358.08M | 151.09M | - | 0 | -125.04M | -0.83 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Erasca News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/29/2024 | 10:55 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 5/17/2024 | 16:07 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 5/17/2024 | 05:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/16/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 5/16/2024 | 15:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/15/2024 | 14:52 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 5/09/2024 | 15:18 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 5/09/2024 | 15:14 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 5/08/2024 | 15:12 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/08/2024 | 15:08 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/15/2024 | 13:10 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 2/13/2024 | 19:24 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ERAS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.47 | 2.70 | 2.31 | 2.56 | 1,566,083 | -0.095 | -3.85% |
| 1 Month | 1.97 | 2.9185 | 1.81 | 2.35 | 3,628,832 | 0.405 | 20.56% |
| 3 Months | 2.08 | 2.9185 | 1.74 | 2.28 | 1,604,253 | 0.295 | 14.18% |
| 6 Months | 1.90 | 2.9185 | 1.64 | 2.18 | 1,290,445 | 0.475 | 25.00% |
| 1 Year | 3.01 | 3.16 | 1.51 | 2.23 | 1,021,240 | -0.635 | -21.10% |
| 3 Years | 15.90 | 24.47 | 1.51 | 5.57 | 801,828 | -13.53 | -85.06% |
| 5 Years | 15.90 | 24.47 | 1.51 | 5.57 | 801,828 | -13.53 | -85.06% |
Erasca Description
| Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. |
